Cargando…

SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques

The development of radiotracers for use in vivo to image β-amyloid (Aβ) plaques in cases of Alzheimer's disease (AD) is an important, active area of research. The presence of Aβ aggregates in the brain is generally accepted as a hallmark of AD. Since the only definitive diagnosis of AD is by po...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Masahiro, Saji, Hideo
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094870/
https://www.ncbi.nlm.nih.gov/pubmed/21603239
http://dx.doi.org/10.1155/2011/543267
_version_ 1782203604862500864
author Ono, Masahiro
Saji, Hideo
author_facet Ono, Masahiro
Saji, Hideo
author_sort Ono, Masahiro
collection PubMed
description The development of radiotracers for use in vivo to image β-amyloid (Aβ) plaques in cases of Alzheimer's disease (AD) is an important, active area of research. The presence of Aβ aggregates in the brain is generally accepted as a hallmark of AD. Since the only definitive diagnosis of AD is by postmortem staining of affected brain tissue, the development of techniques which enable one to image Aβ plaques in vivo has been strongly desired. Furthermore, the quantitative evaluation of Aβ plaques in the brain could facilitate evaluation of the efficacy of antiamyloid therapies currently under development. This paper reviews the current situation in the development of agents for SPECT-based imaging of Aβ plaques in Alzheimer's brains.
format Text
id pubmed-3094870
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30948702011-05-20 SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques Ono, Masahiro Saji, Hideo Int J Mol Imaging Review Article The development of radiotracers for use in vivo to image β-amyloid (Aβ) plaques in cases of Alzheimer's disease (AD) is an important, active area of research. The presence of Aβ aggregates in the brain is generally accepted as a hallmark of AD. Since the only definitive diagnosis of AD is by postmortem staining of affected brain tissue, the development of techniques which enable one to image Aβ plaques in vivo has been strongly desired. Furthermore, the quantitative evaluation of Aβ plaques in the brain could facilitate evaluation of the efficacy of antiamyloid therapies currently under development. This paper reviews the current situation in the development of agents for SPECT-based imaging of Aβ plaques in Alzheimer's brains. Hindawi Publishing Corporation 2011 2011-04-13 /pmc/articles/PMC3094870/ /pubmed/21603239 http://dx.doi.org/10.1155/2011/543267 Text en Copyright © 2011 M. Ono and H. Saji. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Ono, Masahiro
Saji, Hideo
SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques
title SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques
title_full SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques
title_fullStr SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques
title_full_unstemmed SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques
title_short SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques
title_sort spect imaging agents for detecting cerebral β-amyloid plaques
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094870/
https://www.ncbi.nlm.nih.gov/pubmed/21603239
http://dx.doi.org/10.1155/2011/543267
work_keys_str_mv AT onomasahiro spectimagingagentsfordetectingcerebralbamyloidplaques
AT sajihideo spectimagingagentsfordetectingcerebralbamyloidplaques